AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24969368 — intervention group
Group type: EXPERIMENTAL
Intervention: Jia‐Wei‐Xiao‐Yao‐San (JWXYS) with Leonurus heterophyllus Sweet
Number of subjects: 14312
Study 24969368 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyperus rotundus L. with Leonurus heterophyllus Sweet
Number of subjects: 14312
Study 22131999 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass Allergy Immunotherapy Tablet (AIT) with CED
Number of subjects: 261
Study 22131999 — intervention group
Group type: COMPARATOR
Intervention: Grass Allergy Immunotherapy Tablet (AIT) without CED
Number of subjects: 261
Study 20855244 — intervention group
Group type: EXPERIMENTAL
Intervention: Shengmai capsule
Number of subjects: 0
Study 20855244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18763243 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-coated lightweight mesh
Number of subjects: 317
Study 18763243 — intervention group
Group type: COMPARATOR
Intervention: Standard polypropylene mesh
Number of subjects: 317
Study 18763243 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 317
Study 16275616 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg/daily)
Number of subjects: 30
Study 16275616 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg/daily)
Number of subjects: 30
Study 16275616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12594141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 5 mg ml(‐1) (with glucose 50 mg ml(‐1)), 3 ml
Number of subjects: 40
Study 12594141 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 5 mg ml(‐1) (with glucose 80 mg ml(‐1)), 3 ml
Number of subjects: 40
Study 11064438 — intervention group
Group type: EXPERIMENTAL
Intervention: IV administration of synthetic peptide MBP82-98 (DEN(85)VVHFFKNIVTP(96)RT)
Number of subjects: 56
Study 11064438 — intervention group
Group type: COMPARATOR
Intervention: IV saline injections every 6 months for the first 2 years
Number of subjects: 56
Study 8759564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (Zantac effervescent tablets) 150 mg bd for two weeks, increased to qds for non-responders in the last two weeks.
Number of subjects: 0
Study 8759564 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (Zantac effervescent tablets)
Number of subjects: 0
Study 1290245 — intervention group
Group type: EXPERIMENTAL
Intervention: Accupro monotherapy (5 mg to 40 mg daily)
Number of subjects: 108
Study 1290245 — intervention group
Group type: EXPERIMENTAL
Intervention: Accupro combined with Diltiazem or a diuretic
Number of subjects: 108
Study 1290245 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-recorded blood pressure measurements
Number of subjects: 108
Study 1290245 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-recordings taken twice a day
Number of subjects: 108
Study 1290245 — intervention group
Group type: COMPARATOR
Intervention: Casual office readings
Number of subjects: 108
Study 6405494 — intervention group
Group type: EXPERIMENTAL
Intervention: ProcalAmine (3% amino acids, 3% glycerol, complete maintenance electrolytes)
Number of subjects: 100
Study 6405494 — intervention group
Group type: COMPARATOR
Intervention: FreAmine III (isonitrogenous amino acid control solution)
Number of subjects: 100
Study 28345961 — intervention group
Group type: EXPERIMENTAL
Intervention: SHUTi (Internet-based cognitive-behavioral treatment for insomnia)
Number of subjects: 181
Study 28345961 — intervention group
Group type: COMPARATOR
Intervention: Patient education (control group)
Number of subjects: 181
Study 30501620 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT/FO-derived n-3 PUFAs (test group)
Number of subjects: 42
Study 30501620 — intervention group
Group type: COMPARATOR
Intervention: MCT/LCT (control group)
Number of subjects: 42
Study 30501620 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 26453051 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggression chemosignal from boxing session
Number of subjects: 38
Study 26453051 — intervention group
Group type: COMPARATOR
Intervention: Exercise chemosignal from ergometer session
Number of subjects: 38
Study 26453051 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemosignals of aggression presented to normosmic participants
Number of subjects: 38
Study 24391123 — intervention group
Group type: EXPERIMENTAL
Intervention: Video goggles (watching a favorite movie during the dental visit using sunglass-style video eyewear)
Number of subjects: 80
Study 24391123 — intervention group
Group type: EXPERIMENTAL
Intervention: Video peer modeling (watching a DVD recording of a typically developing child undergoing a dental visit)
Number of subjects: 80
Study 24391123 — intervention group
Group type: EXPERIMENTAL
Intervention: Video peer modeling plus video goggles
Number of subjects: 80
Study 24391123 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 80
Study 23110320 — intervention group
Group type: EXPERIMENTAL
Intervention: A(H1N1)pmd09 vaccine co-administered with TIV
Number of subjects: 871
Study 23110320 — intervention group
Group type: EXPERIMENTAL
Intervention: A(H1N1)pmd09 vaccine sequentially administered with TIV
Number of subjects: 871
Study 23110320 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted A(H1N1)pmd09 vaccine
Number of subjects: 871
Study 23110320 — intervention group
Group type: COMPARATOR
Intervention: TIV
Number of subjects: 871
Study 23110320 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted A(H1N1)pmd09 vaccine
Number of subjects: 871
Study 23110320 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted A(H1N1)pmd09 vaccine
Number of subjects: 871
Study 20594308 — intervention group
Group type: EXPERIMENTAL
Intervention: Six self‐management group sessions provided by a multi‐disciplinary team (occupational therapist, physiotherapist, dietician, specialized nurse) for six weeks
Number of subjects: 170
Study 20594308 — intervention group
Group type: COMPARATOR
Intervention: Two group sessions and four sessions by telephone provided by a specialized nurse and physiotherapist for six weeks
Number of subjects: 170
Study 20594308 — intervention group
Group type: EXPERIMENTAL
Intervention: Six self‐management group sessions
Number of subjects: 170
Study 20594308 — intervention group
Group type: COMPARATOR
Intervention: Two group sessions and four sessions by telephone
Number of subjects: 170
Study 17077346 — intervention group
Group type: COMPARATOR
Intervention: Hyperinsulinemic euglycemic clamp in healthy nonobese women
Number of subjects: 22
Study 17077346 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic clamp in insulin-resistant obese women
Number of subjects: 22
Study 15755853 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (4.3 g or 40 mmol/d)
Number of subjects: 18
Study 15755853 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium citrate (800 mg or 20 mmol/d)
Number of subjects: 18
Study 15755853 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (potassium citrate and calcium citrate)
Number of subjects: 18
Study 15755853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12062733 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg twice daily (n = 17)
Number of subjects: 25
Study 12062733 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 25
Study 11247166 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet supplemented with PUFA omega-3 (Eiconol) 8 g/day
Number of subjects: 60
Study 8751516 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated cardiopulmonary bypass system (Duraflo II)
Number of subjects: 50
Study 8751516 — intervention group
Group type: COMPARATOR
Intervention: Standard noncoated control system
Number of subjects: 50
Study 1501618 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatoportoenterostomy (Kasai procedure)
Number of subjects: 15
Study 1501618 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical therapy (no Kasai procedure)
Number of subjects: 15
Study 1501618 — intervention group
Group type: COMPARATOR
Intervention: Healthy children (control group)
Number of subjects: 15
Study 2859255 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of salbutamol plus oxatomide
Number of subjects: 40
Study 2859255 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol alone
Number of subjects: 40
Study 30885775 — intervention group
Group type: EXPERIMENTAL
Intervention: MRE11 protein levels assessed by immunohistochemistry (IHC) in BCON trial (n=132)
Number of subjects: 373
Study 30885775 — intervention group
Group type: EXPERIMENTAL
Intervention: MRE11 protein levels assessed by immunohistochemistry (IHC) in BC2001 trial (n=221)
Number of subjects: 373
Study 30885775 — intervention group
Group type: EXPERIMENTAL
Intervention: Reoptimized staining in BCON tissue microarrays (n=116)
Number of subjects: 373
Study 29462058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided paravertebral block (USG)
Number of subjects: 72
Study 29462058 — intervention group
Group type: COMPARATOR
Intervention: Anatomical landmark technique (ALT)
Number of subjects: 72
Study 26780408 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal dose of mepivacaine 108 mg with epinephrine 54 μg (group I)
Number of subjects: 21
Study 26780408 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal dose of mepivacaine 216 mg with epinephrine 108 μg (group II)
Number of subjects: 21
Study 26780408 — intervention group
Group type: COMPARATOR
Intervention: Both groups (I and II)
Number of subjects: 21
Study 24629885 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-based texting aftercare intervention
Number of subjects: 80
Study 24629885 — intervention group
Group type: COMPARATOR
Intervention: Aftercare as usual control condition
Number of subjects: 80
Study 22419500 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic longitudinal cohort study with assessments at baseline, after three and six years of follow-up.
Number of subjects: 1120
Study 20347225 — intervention group
Group type: EXPERIMENTAL
Intervention: Substantial pain intensity reduction (50% pain reduction)
Number of subjects: 2575
Study 20347225 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate pain intensity reduction (30% to <50% pain reduction)
Number of subjects: 2575
Study 18055678 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 g/kg per day amino acid supplementation
Number of subjects: 122
Study 18055678 — intervention group
Group type: COMPARATOR
Intervention: 2.5 g/kg per day amino acid supplementation
Number of subjects: 122
Study 15632536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (group F, n = 60)
Number of subjects: 120
Study 15632536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl combined with bupivacaine infiltration (group FB, n = 60)
Number of subjects: 120
Study 12383453 — intervention group
Group type: EXPERIMENTAL
Intervention: IV catheter blood sampling
Number of subjects: 12
Study 12383453 — intervention group
Group type: COMPARATOR
Intervention: Needle stick blood sampling
Number of subjects: 12
Study 12383453 — intervention group
Group type: EXPERIMENTAL
Intervention: IV catheter blood sampling with difficulties
Number of subjects: 12
Study 12383453 — intervention group
Group type: EXPERIMENTAL
Intervention: IV catheter blood sampling during sleep
Number of subjects: 12
Study 10215955 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal DDAVP (300 microg)
Number of subjects: 10
Study 10215955 — intervention group
Group type: COMPARATOR
Intervention: FVIII only
Number of subjects: 10
Study 7486483 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (600 mg twice daily for 12 months)
Number of subjects: 29
Study 7486483 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 12 months)
Number of subjects: 29
Study 2278056 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg dose of quinine, quinidine and cinchonine combination
Number of subjects: 13
Study 2278056 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg dose of quinine, quinidine and cinchonine combination
Number of subjects: 13
Study 2278056 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 13
Study 31320735 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone implant (IVD)
Number of subjects: 43
Study 31320735 — intervention group
Group type: COMPARATOR
Intervention: Systemic steroids
Number of subjects: 43
Study 31146083 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis (pos/neg)
Number of subjects: 91
Study 31146083 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration ratio (CR) cut-off of 0.5
Number of subjects: 91
Study 28240240 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing enzymes and proteins
Number of subjects: 0
Study 28240240 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste
Number of subjects: 0
Study 24799074 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril erbumine (PE)
Number of subjects: 24
Study 24799074 — intervention group
Group type: COMPARATOR
Intervention: Perindopril arginine (PA)
Number of subjects: 24
Study 24138347 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Action (PA)
Number of subjects: 0
Study 21449624 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Renal Alert Pharmacy (DRAP) program
Number of subjects: 6125
Study 21449624 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 6125
Study 18798228 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity with binge eating
Number of subjects: 374
Study 18798228 — intervention group
Group type: COMPARATOR
Intervention: Obesity without binge eating
Number of subjects: 374
Study 18798228 — intervention group
Group type: COMPARATOR
Intervention: Causal beliefs (psychological, biological addiction, ambiguous)
Number of subjects: 374
Study 16902049 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.15 mg/kg
Number of subjects: 166
Study 16902049 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg/kg (15 mg maximum)
Number of subjects: 166
Study 16902049 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) placebo
Number of subjects: 166
Study 15204056 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory working memory task
Number of subjects: 0
Study 15204056 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual working memory task
Number of subjects: 0
Study 15204056 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous visual and auditory working memory tasks
Number of subjects: 0
Study 15204056 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual working memory task
Number of subjects: 0
Study 16136902 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term domiciliary oxygen therapy (LTDOT)
Number of subjects: 61
Study 16136902 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine treatment only)
Number of subjects: 61
Study 9597374 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin up to 2000 mg/day
Number of subjects: 60
Study 9597374 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin 40 mg daily (control)
Number of subjects: 60
Study 9597374 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 60
Study 7871082 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam 0.026 mg/kg
Number of subjects: 60
Study 7871082 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam 0.038 mg/kg
Number of subjects: 60
Study 7871082 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 0.2 mg/kg
Number of subjects: 60
Study 7871082 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 0.3 mg/kg
Number of subjects: 60
Study 7871082 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 3209284 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine 5 micrograms kg‐1 90 min before induction of anesthesia
Number of subjects: 40
Study 3209284 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (Control)
Number of subjects: 40
Study 29516486 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone 1 mg IV
Number of subjects: 127
Study 29516486 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine 10 mg + diphenhydramine 25 mg IV
Number of subjects: 127
Study 28409385 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary folic acid 1.0 mg/kg
Number of subjects: 18
Study 28409385 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary folic acid 2.0 mg/kg
Number of subjects: 18
Study 28409385 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary folic acid 5.0 mg/kg
Number of subjects: 18
Study 28409385 — intervention group
Group type: COMPARATOR
Intervention: Dietary folic acid (0.0 mg/kg)
Number of subjects: 18
Study 26213796 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Number of subjects: 646
Study 26213796 — intervention group
Group type: COMPARATOR
Intervention: Active comparison treatments
Number of subjects: 646
Study 23579349 — intervention group
Group type: EXPERIMENTAL
Intervention: HF toolkit, 2 onsite meetings, and a monthly phone call
Number of subjects: 591
Study 23579349 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher nurse-turnover
Number of subjects: 591
Study 23579349 — intervention group
Group type: EXPERIMENTAL
Intervention: Better practice environment
Number of subjects: 591
Study 20215539 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression signature of 97 cell death genes
Number of subjects: 1058
Study 20215539 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-gene expression signature derived from the 97-gene signature
Number of subjects: 1058
Study 20215539 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous deletions in genes
Number of subjects: 1058
Study 18055007 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based, stage-matched multiple behavior interventions
Number of subjects: 1277
Study 17459288 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐percent lactic acid mouthwash (group A)
Number of subjects: 70
Study 17459288 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water mouthwash, group B)
Number of subjects: 70
Study 12792007 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback reports combined with outreach visits from trained non‐physicians
Number of subjects: 185
Study 12792007 — intervention group
Group type: COMPARATOR
Intervention: No special attention (control group)
Number of subjects: 185
Study 10805362 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (N=58)
Number of subjects: 157
Study 10805362 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (N=99)
Number of subjects: 157
Study 10805362 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of vaginal white blood cells or mucopus
Number of subjects: 157
Study 8870165 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dietary lifestyle intervention (25% of total calories from fat)
Number of subjects: 174
Study 8870165 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 174
Study 8870165 — intervention group
Group type: EXPERIMENTAL
Intervention: New enzyme immunoassay (EIA) for measurement of 2‐ and 16 alpha‐hydroxyestrone
Number of subjects: 174
Study 1642580 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed mini-dose warfarin (1 mg daily)
Number of subjects: 200
Study 1642580 — intervention group
Group type: COMPARATOR
Intervention: Adjusted-dose warfarin (to maintain INR of 2.0-4.0)
Number of subjects: 200
Study 1642580 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 200
Study 1642580 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted-dose warfarin
Number of subjects: 200
Study 6402612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin sodium (3 doses)
Number of subjects: 0
Study 6402612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30690289 — intervention group
Group type: EXPERIMENTAL
Intervention: Short term life review intervention
Number of subjects: 109
Study 30690289 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo (control group)
Number of subjects: 109
Study 30431520 — intervention group
Group type: EXPERIMENTAL
Intervention: Active left DLPFC rTMS
Number of subjects: 30
Study 30431520 — intervention group
Group type: COMPARATOR
Intervention: Sham left DLPFC rTMS
Number of subjects: 30
Study 26581442 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 8% patch
Number of subjects: 559
Study 26581442 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 559
Study 24554005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2411
Study 24554005 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2411
Study 24554005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2411
Study 22243768 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-millisecond pulse duration and 9 J/cm²
Number of subjects: 20
Study 22243768 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45-millisecond pulse duration and 6 J/cm²
Number of subjects: 20
Study 20639632 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (1,500 mg daily for 3 months)
Number of subjects: 29
Study 20639632 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group, 31 patients)
Number of subjects: 29
Study 18556425 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT‐IVTJ (subthreshold grid laser treatment combined with intravitreal triamcinolone injection)
Number of subjects: 24
Study 18556425 — intervention group
Group type: COMPARATOR
Intervention: SGLT (subthreshold grid laser treatment)
Number of subjects: 24
Study 17851262 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 60 mg/body/day (level 1)
Number of subjects: 21
Study 17851262 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 80 mg/body/day (recommended dose)
Number of subjects: 21
Study 17851262 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 100 mg/body/day (level 3)
Number of subjects: 21
Study 12802000 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta 1a
Number of subjects: 144
Study 12802000 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 144
Study 10733159 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of tetragastrin
Number of subjects: 0